'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Lupin has increased 12.59% to Rs 5672.73 crore. Sales of Pharmaceuticals segment has gone up 12.47% to Rs 5,647.20 crore (accounting for 99.54% of total sales). Sales of others segment has gone up 48.33% to Rs 26.24 crore (accounting for 0.46% of total sales). Inter-segment sales rose Rs 0.01 crore to Rs 0.71 crore.
Profit before interest, tax and other unallocable items (PBIT) has jumped 67.53% to Rs 1,054.86 crore. PBIT of Pharmaceuticals segment rose 65.29% to Rs 1,089.01 crore (accounting for 103.24% of total PBIT). PBIT of others segment fell 16.99% to Rs -34.15 crore (accounting for -3.24% of total PBIT).
PBIT margin of Pharmaceuticals segment rose from 13.12% to 19.28%. PBIT margin of others segment rose from ...
Pleaselogin & subscribe to view the full report.
More Reports
-
Net Sales up 7.1% YoY to Rs 1313.05 cr, Net profit up 34.3% YoY to Rs 204.66 cr in Q3FY2025
-
(05-Feb-2025)
Abbott India
-
(05-Feb-2025)
Titan Company
-
VNB up 9%, margins eases to 23.2% in 9MFY2025
|
|